RxDoctor Payments Data

Russell Silver

Physical Medicine & Rehabilitation · New York, NYNPI 1053377796

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $27,260 of the $34,326 with a category attached, or 79.4%. Amgen accounts for 67.0% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $24,848 and has fallen 99.9% since, to $31 in 2025. Among physical medicine & rehabilitation clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$34,326in general payments, 2019–2025

Across 410 payments — averaging $83.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$23K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$7K
  • Redhill Biopharma Inc.$901
  • Scilex Pharmaceuticals Inc.$781
  • Daiichi Sankyo Inc.$596
  • Pfizer$392
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$8302%
  • Speaking & faculty fees$27,26079%
  • Travel & lodging$6982%
  • Food & beverage$5,53716%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,326 in reported general payments places this provider in the 95th percentile of 872 physical medicine & rehabilitation providers in New York.

See all physical medicine & rehabilitation providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide13$29,688
Diclofenac Sodium66$14,820
MounjaroTirzepatide14$13,237
OzempicSemaglutide14$13,025
OxycontinOxycodone Hcl12$10,852
MovantikNaloxegol Oxalate16$10,697
Chlorzoxazone35$10,324
Fentanyl14$7,496
Lidocaine44$3,070
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen103$3,019
Oxycodone Hcl58$3,007
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen37$1,008
Naloxone Hcl12$730
Meloxicam87$350
Tramadol Hcl31$343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$7,309$29,68813 claims
Redhill Biopharma Inc.Movantik$901$10,69716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 872 physical medicine & rehabilitation providers in New York.

Other physical medicine & rehabilitation in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →